BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 19223501)

  • 1. Utility of incorporating genetic variants for the early detection of prostate cancer.
    Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
    Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of genetic markers to determine risk for prostate cancer at prostate biopsy.
    Nam RK; Zhang WW; Jewett MA; Trachtenberg J; Klotz LH; Emami M; Sugar L; Sweet J; Toi A; Narod SA
    Clin Cancer Res; 2005 Dec; 11(23):8391-7. PubMed ID: 16322300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
    Nam RK; Zhang WW; Trachtenberg J; Jewett MA; Emami M; Vesprini D; Chu W; Ho M; Sweet J; Evans A; Toi A; Pollak M; Narod SA
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1429-37. PubMed ID: 14693733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection.
    Nam RK; Zhang WW; Trachtenberg J; Diamandis E; Toi A; Emami M; Ho M; Sweet J; Evans A; Jewett MA; Narod SA
    J Clin Oncol; 2003 Jun; 21(12):2312-9. PubMed ID: 12805332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
    Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
    Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.
    Nam RK; Zhang WW; Klotz LH; Trachtenberg J; Jewett MA; Sweet J; Toi A; Teahan S; Venkateswaran V; Sugar L; Loblaw A; Siminovitch K; Narod SA
    Clin Cancer Res; 2006 Nov; 12(21):6452-8. PubMed ID: 17085659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
    Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing individual risk for prostate cancer.
    Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Appu S; Loblaw DA; Sugar L; Narod SA; Kattan MW
    J Clin Oncol; 2007 Aug; 25(24):3582-8. PubMed ID: 17704405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
    Nam RK; Toi A; Trachtenberg J; Klotz LH; Jewett MA; Emami M; Sugar L; Sweet J; Pond GR; Narod SA
    J Urol; 2006 Feb; 175(2):489-94. PubMed ID: 16406978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
    Kawakami S; Koga F; Fujii Y; Saito K; Yamamoto S; Tatokoro M; Yonese J; Kageyama Y; Fukui I; Kihara K
    Int J Urol; 2008 Dec; 15(12):1055-60. PubMed ID: 19054174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
    Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
    Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy.
    Issa MM; Zasada W; Ward K; Hall JA; Petros JA; Ritenour CW; Goodman M; Kleinbaum D; Mandel J; Marshall FF
    Cancer Detect Prev; 2006; 30(3):269-75. PubMed ID: 16844319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
    Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Loblaw A; Pond GR; Emami M; Sugar L; Sweet J; Narod SA
    Can J Urol; 2006 Apr; 13 Suppl 2():2-10. PubMed ID: 16672122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
    Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
    Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer.
    Chen YC; Giovannucci E; Lazarus R; Kraft P; Ketkar S; Hunter DJ
    Cancer Res; 2005 Dec; 65(24):11771-8. PubMed ID: 16357190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
    Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
    Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer.
    Levin AM; Zuhlke KA; Ray AM; Cooney KA; Douglas JA
    Prostate; 2007 Oct; 67(14):1507-13. PubMed ID: 17683075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.